User login
Key clinical point: Therapy with atezolizumab plus bevacizumab (Atez/Bev) vs. lenvatinib in the first-line setting may confer a survival benefit in patients with unresectable hepatocellular carcinoma (uHCC).
Major finding: Patients receiving Atez/Bev vs. lenvatinib showed better overall survival (1 year: 67.2% vs. 66.2%; 1.5 years: 58.1% vs. 52.7%; P = .002) and progression-free survival (1 year: 31.6% vs. 20.4%; 1.5 years: non-estimable vs. 11.2%; P < .0001) rates.
Study details: This retrospective study included 251 systemic treatment-naive patients with uHCC who received standard-dose Atez/Bev (n = 194) or lenvatinib (n = 57).
Disclosures: The study did not receive any funding. Some authors declared serving as advisors or receiving lecture fees or research funding from various sources.
Source: Hiraoka A et al. Does first-line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib .Cancer Med. 2022 (Jun 3). Doi: 10.1002/cam4.4854
Key clinical point: Therapy with atezolizumab plus bevacizumab (Atez/Bev) vs. lenvatinib in the first-line setting may confer a survival benefit in patients with unresectable hepatocellular carcinoma (uHCC).
Major finding: Patients receiving Atez/Bev vs. lenvatinib showed better overall survival (1 year: 67.2% vs. 66.2%; 1.5 years: 58.1% vs. 52.7%; P = .002) and progression-free survival (1 year: 31.6% vs. 20.4%; 1.5 years: non-estimable vs. 11.2%; P < .0001) rates.
Study details: This retrospective study included 251 systemic treatment-naive patients with uHCC who received standard-dose Atez/Bev (n = 194) or lenvatinib (n = 57).
Disclosures: The study did not receive any funding. Some authors declared serving as advisors or receiving lecture fees or research funding from various sources.
Source: Hiraoka A et al. Does first-line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib .Cancer Med. 2022 (Jun 3). Doi: 10.1002/cam4.4854
Key clinical point: Therapy with atezolizumab plus bevacizumab (Atez/Bev) vs. lenvatinib in the first-line setting may confer a survival benefit in patients with unresectable hepatocellular carcinoma (uHCC).
Major finding: Patients receiving Atez/Bev vs. lenvatinib showed better overall survival (1 year: 67.2% vs. 66.2%; 1.5 years: 58.1% vs. 52.7%; P = .002) and progression-free survival (1 year: 31.6% vs. 20.4%; 1.5 years: non-estimable vs. 11.2%; P < .0001) rates.
Study details: This retrospective study included 251 systemic treatment-naive patients with uHCC who received standard-dose Atez/Bev (n = 194) or lenvatinib (n = 57).
Disclosures: The study did not receive any funding. Some authors declared serving as advisors or receiving lecture fees or research funding from various sources.
Source: Hiraoka A et al. Does first-line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib .Cancer Med. 2022 (Jun 3). Doi: 10.1002/cam4.4854